Otros idiomas Galectin Therapeutics Inc.

Acciones

GALT

US3632252025

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 26/04/2024			Varia. Cinco días.	Varia. 1 de enero.
3,45 ^USD	-1,43 %		+2,37 %	+107,83 %

29/03	Galectin Therapeutics Inc. nombra a Benjamin S. Carson miembro del Consejo de Administración	CI
29/03	Galectin Therapeutics Inc. presenta los resultados del ejercicio cerrado el 31 de diciembre de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Galectin Therapeutics : Corporate Presentation, April 2024	17/04
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension	10/04
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis	09/04
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update	01/04
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update	29/03
Galectin Therapeutics Inc. Appoints Benjamin S. Carson as Member of the Board of Directors	29/03
Galectin Therapeutics : Reports 2023 Financial Results and Provides Business Update - Form 8-K	29/03
Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
North American Morning Briefing : Stocks Set for -2-	28/03
Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development	12/03
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update	13/11
Galectin Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
North American Morning Briefing : Stock Futures -2-	13/11
Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD	03/11
Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023	23/10/23
Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors	12/10/23
Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension	04/10/23
Galectin Says Data and Safety Monitoring Board Approves Continuation of Belapectin Study Without Modifications.	03/10/23
Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis	03/10/23
Galectin Therapeutics, Inc. Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE	03/10/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Galectin Therapeutics Inc.

Acciones

GALT

US3632252025

Otros idiomas

Filtros